NewsEpisurf Medical’s 3D-based damage assessment tool: positive development in US patenting

Episurf Medical pursues patent applications (not yet published) within the area of 3D-based assessment of joint lesions. In the US patent granting procedure, the USPTO has in an examiner interview informed Episurf Medical of the intention to issue notice of allowance provided minor amendments are made to the filed claims.

“Whereas the USPTO does not warrant any outcome of a patent application before a final grant decision has been formally issued, the examination progress is very positive for Episurf. This will then be the first patent to be approved for Episurf Medical in the area of damage marking and 3D visualisation of joint damage, which is an awaited milestone for the company” says Pål Ryfors, acting CEO, Episurf Medical.

For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 709 62 36 69